PPARA and Huntington disease: We found no changes in body weight in peroxisome proliferator-activated receptor (PPAR) agonists treated mice in comparison to non-treated HD mice, while maximum, as well as normalized grip strength evaluation, indicated higher values of these parameters in HD treated with rosiglitazone (Figure 1A–C).